Glucocorticoid-induced ocular hypertension: origins and new approaches to minimize

Thomas Yorio, Gaurang C. Patel, Abbot F. Clark

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Introduction: Glucocorticoids (GCs) have unique actions in their combined anti-inflammatory and immunosuppressive activities and are among the most commonly prescribed drugs, particularly for inflammatory conditions. They are often used clinically to treat inflammatory eye diseases like uveitis, optic neuritis, conjunctivitis, keratitis, and others, but are often accompanied by side effects, like ocular hypertension that can be vision threatening. Areas covered: The review will focus on the complex molecular mechanism of action of GCs that involve both transactivation and transrepression and their use therapeutically that can cause significant systemic side effects, particularly ocular hypertension that can lead to glaucoma. Expert Opinion: While we are still unclear as to all the mechanisms responsible for GC-induced ocular hypertension, however, there are potential novel therapies that are in development that can separate some of the anti-inflammatory therapeutic efficacy from their ocular hypertension side effect. This review provides some insight into these approaches.

Original languageEnglish
Pages (from-to)145-157
Number of pages13
JournalExpert Review of Ophthalmology
Issue number3
StatePublished - 3 May 2020


  • Glucocorticoids
  • SEGRAs
  • glaucoma
  • glucocorticoid molecular mechanisms
  • ocular hypertension


Dive into the research topics of 'Glucocorticoid-induced ocular hypertension: origins and new approaches to minimize'. Together they form a unique fingerprint.

Cite this